Innovent's weight-loss drug highlights China challenge for Novo, Lilly – Reuters

Written by

admin

in

  1. Innovent’s weight-loss drug highlights China challenge for Novo, Lilly  Reuters
  2. China approves world’s first dual GCG/GLP-1 receptor for glycemic control in type 2 diabetes  BioSpectrum Asia
  3. World’s First Dual GCG/GLP-1 Drug Shows 87.4% Success Rate: Innovent’s Mazdutide Approved in China  Stock Titan
  4. Innovent Biologics’ Mazdutide Approved in China for Type 2 Diabetes  TipRanks

Continue Reading

More posts